| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neuro-Oncology Clinic, Departments of Oncology and Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Thirty-one (23%) of 137 patients treated for leptomeningeal metastases (LM) achieved a sustained off-therapy response of at least 6 months' duration following treatment by a standard protocol. Of the 31 patients, equal distribution was found among various tumors: lymphoma, 13/44 (29%); breast carcinoma, 10/51 (20%); and other tumors, 8/42 (19%). Neuroimaging of the neuraxis disclosed subarachnoid deposits in 70%, with unexpected findings in 55%. At withdrawal of therapy, all 13 patients with lymphomas had achieved a complete response, and for those with the other tumors, 61% had a partial response. Off-therapy relapse was unrelated to the type of attained response and occurred in nine patients (29%) after a median time of 12 months. Five patients obtained a second prolonged response, mainly by systemic therapy. All eight patients who received only systemic therapy for their LM responded to treatment, four with a complete response. All others received both systemic and intra-CSF treatment and maintained a systemic response. Delayed complications occurred in 58%, with leukoencephalopathy equally affecting patients exposed and patients not exposed to cranial irradiation. The median survival of the whole group was 23 months. We conclude that in LM (lymphomas excluded), a partial response is compatible with a prolonged off-therapy response. Since LM may respond to systemic treatment, the role of intra-CSF therapy, with its associated complications, deserves a prospective reevaluation.
Address correspondence and reprint requests to Dr. Tali Siegal, Neuro-Oncology Clinic, Hadassah University Hospital, P.O. Box 12000, Jerusalem 91120, Israel.
Received October 27, 1993. Accepted in final form February 2, 1994.
This article has been cited by other articles:
|
|
 |
|
  M. C. Chamberlain Neoplastic Meningitis Oncologist, September 1, 2008; 13(9): 967 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Chamberlain Neoplastic Meningitis J. Clin. Oncol., May 20, 2005; 23(15): 3605 - 3613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]
|
|
|
|
|
|
R. J. van Oostenbrugge, A. H. N. Hopman, J. W. Arends, F. C. S. Ramaekers, and A. Twijnstra Treatment of Leptomeningeal Metastases Evaluated by Interphase Cytogenetics J. Clin. Oncol., May 10, 2000; 18(10): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Chamberlain and P. Kormanik Carcinoma Meningitis Secondary to Non-Small Cell Lung Cancer: Combined Modality Therapy Arch Neurol, April 1, 1998; 55(4): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain Carcinomatous Meningitis Arch Neurol, January 1, 1997; 54(1): 16 - 17. [Abstract] [PDF]
|
|
|
|
|
|
M. Balm and J. Hammack Leptomeningeal Carcinomatosis: Presenting Features and Prognostic Factors Arch Neurol, July 1, 1996; 53(7): 626 - 632. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
